Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

James Larkin*, David Minor, Sandra D'Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald Linette, Bartosz Chmielowski, Christopher D. Lao, Paul Lorigan, Kenneth Grossmann, Jessica C. Hassel, Mario Sznol, Adil Daud, Jeffrey Sosman, Nikhil Khushalani, Dirk Schadendorf, Christoph Hoeller, Dana WalkerGeorge Kong, Christine Horak, Jeffrey Weber

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

227 Scopus citations

Fingerprint

Dive into the research topics of 'Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences